Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
26 11 2019
26 11 2019
Historique:
received:
30
08
2019
accepted:
15
10
2019
entrez:
19
11
2019
pubmed:
19
11
2019
medline:
9
9
2020
Statut:
ppublish
Résumé
Myelodysplastic syndromes (MDS) are hematopoietic stem cell malignancies. Known predisposing factors to adult MDS include rare germline mutations, cytotoxic therapy, age-related clonal hematopoiesis, and autoimmune or chronic inflammatory disorders. To date, no published studies characterizing MDS-associated germline susceptibility polymorphisms exist. We performed a genome-wide association study of 2 sample sets (555 MDS cases vs 2964 control subjects; 352 MDS cases vs 2640 control subjects) in non-del(5q) MDS cases of European genomic ancestry. Meta-analysis identified 8 MDS-associated loci at 1q31.1 (PLA2G4A), 3p14.1 (FAM19A4), 5q21.3 (EFNA5), 6p21.33, 10q23.1 (GRID1), 12q24.32, 15q26.1, and 20q13.12 (EYA2) that approached genome-wide significance. Gene expression for 5 loci that mapped within or near genes was significantly upregulated in MDS bone marrow cells compared with those of control subjects (P < .01). Higher PLA2G4A expression and lower EYA2 expression were associated with poorer overall survival (P = .039 and P = .037, respectively). Higher PLA2G4A expression is associated with mutations in NRAS (P < .001), RUNX1 (P = .012), ASXL1 (P = .007), and EZH2 (P = .038), all of which are known to contribute to MDS development. EYA2 expression was an independently favorable risk factor irrespective of age, sex, and Revised International Scoring System score (relative risk, 0.67; P = .048). Notably, these genes have regulatory roles in innate immunity, a critical driver of MDS pathogenesis. EYA2 overexpression induced innate immune activation, whereas EYA2 inhibition restored colony-forming potential in primary MDS cells indicative of hematopoietic restoration and possible clinical relevance. In conclusion, among 8 suggestive MDS-associated loci, 5 map to genes upregulated in MDS with functional roles in innate immunity and potential biological relevance to MDS.
Identifiants
pubmed: 31738830
pii: 428769
doi: 10.1182/bloodadvances.2019000922
pmc: PMC6880887
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3579-3589Subventions
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Informations de copyright
© 2019 by The American Society of Hematology.
Références
Cell Cycle. 2005 Jun;4(6):812-7
pubmed: 15970671
Int J Mol Sci. 2016 May 30;17(6):
pubmed: 27248996
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Hematology Am Soc Hematol Educ Program. 2007;:398-404
pubmed: 18024657
Nat Genet. 2016 Oct;48(10):1279-83
pubmed: 27548312
Cell Mol Immunol. 2015 Sep;12(5):615-24
pubmed: 25109685
Nat Genet. 2013 Oct;45(10):1238-1243
pubmed: 24013639
Genet Epidemiol. 2010 Jan;34(1):60-6
pubmed: 19847795
Cancer Res. 2009 Oct 1;69(19):7518-23
pubmed: 19773435
Leukemia. 2015 May;29(5):1051-9
pubmed: 25428263
Cell Metab. 2012 Aug 8;16(2):250-64
pubmed: 22883233
J Biol Chem. 2011 Dec 2;286(48):41862-70
pubmed: 22002058
Nucleic Acids Res. 2016 Jan 4;44(D1):D917-24
pubmed: 26507857
Eur J Haematol. 2007 Dec;79(6):468-76
pubmed: 17976189
J Biomed Sci. 2006 May;13(3):357-71
pubmed: 16468075
Leuk Res. 2011 Jul;35(7):863-7
pubmed: 21396711
Dis Markers. 2015;2015:241301
pubmed: 26491211
Gut. 2017 Apr;66(4):581-587
pubmed: 26701879
PLoS One. 2012;7(4):e34477
pubmed: 22509308
Ann Hematol. 2008 Jul;87(7):537-44
pubmed: 18350294
Biometrika. 2010 Jun;97(2):321-332
pubmed: 23049122
Cell. 2016 Nov 17;167(5):1415-1429.e19
pubmed: 27863252
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Oncotarget. 2017 Aug 24;8(44):77436-77452
pubmed: 29100399
Leuk Res. 2010 Apr;34(4):447-53
pubmed: 19758696
Blood. 2017 Apr 27;129(17):2347-2358
pubmed: 28223278
J Pathol. 2013 Sep;231(1):53-62
pubmed: 23674368
Front Immunol. 2018 Mar 13;9:447
pubmed: 29593718
FEBS Lett. 1997 Jun 23;410(1):49-53
pubmed: 9247121
Clin Cancer Res. 2008 Dec 15;14(24):8070-9
pubmed: 19088022
J Immunol. 1998 Jun 15;160(12):5929-35
pubmed: 9637506
Nat Commun. 2015 Jan 09;6:5901
pubmed: 25574665
Blood. 2011 Apr 28;117(17):4552-60
pubmed: 21285439
Nature. 2009 Jul 23;460(7254):520-4
pubmed: 19561593
J Immunol. 2015 Jun 1;194(11):5472-5487
pubmed: 25917098
Bioinformatics. 2010 Sep 15;26(18):2336-7
pubmed: 20634204
Development. 2016 Feb 1;143(3):461-72
pubmed: 26839344
Leuk Res. 2007 Jun;31(6):783-90
pubmed: 17049984
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Haematologica. 2014 Feb;99(2):282-91
pubmed: 24056813
Mol Cell. 2016 May 19;62(4):479-90
pubmed: 27184077
Nature. 2012 Dec 20;492(7429):369-75
pubmed: 23222517
Blood. 2016 Dec 22;128(25):2960-2975
pubmed: 27737891
PLoS One. 2012;7(8):e42725
pubmed: 22916150